Executional strength is not hiring better people or finding better vendors. It is building systems that allow good people and good vendors to perform. Many biotech organizations assume execution is a function of talent. Hire the best director. Bring in the most experienced CRO. Partner with the leading site network. Yet execution still stalls. The gap between talent and outcome is infrastructure. Kieran Engels works with leadership teams that have recruited exceptional people and partnered with respected vendors, yet timelines slip and costs overrun. The difference between organizations that execute well and those that don’t is not the talent at the table. It is the systems that structure how that talent works together. Executional strength means clear decision rights, defined accountability, regular feedback, and governance systems that surface problems early. These systems can be built. They are not mysterious. But they require intentional investment.

KEY TAKEAWAYS

The Challenge

The assumption in biotech is that execution is a talent problem. If you hire the right person, execution improves. If you find the right vendor, execution follows. But this misses the core issue. Talent and vendors are inputs. Systems are infrastructure.

Executional strength is what happens when systems allow inputs to perform. When decision rights are clear, talent does not waste time negotiating authority. When accountability is singular, vendors know exactly what they are responsible for and what escalation looks like. When feedback is regular, problems surface before they compound.

Let’s be clear. The organizations that execute well are not the ones with more talented people. They are the ones with more mature governance infrastructure.

Kieran Engels has worked with teams that included exceptional people. Directors with 15 years of experience. Vendors with pristine track records. Yet execution was inconsistent. When governance infrastructure was mapped, the pattern became clear. The talented people were spending energy on clarification, negotiation, and firefighting rather than on execution. The infrastructure was not in place to let talent work.

What changed? Not the people. The systems.

A clear example: decision authority. When is a decision made? By whom? Who has the final say? In immature organizations, this is ambiguous. A vendor wants to make a change. The sponsor leadership is unclear who has authority to approve. Debate happens. Time passes. The vendor waits. The timeline slips. This is not a talent problem. It is an infrastructure problem. The answer is a single decision matrix that says: this type of decision is made by this person, with this approval timeline, and here is how dissent is handled.

The Infrastructure

Another example: feedback cadence. How often does the vendor report? How often does the sponsor review? How often does escalation happen? In immature organizations, feedback is annual or quarterly. Problems fester. By the time they surface, they are expensive to fix. In mature organizations, feedback is weekly or daily. Problems are visible early. Adjustments can be made while they are still small.

The third example: accountability clarity. When something goes wrong, who is accountable? In immature organizations, accountability is distributed. The CRO says the sponsor should have been clearer. The sponsor says the CRO should have been more proactive. The site says they were following the protocol. No one owns the outcome. In mature organizations, accountability is singular. A person owns each outcome. That person is named. That person escalates early if they are at risk of missing the outcome.

These are not new concepts. They are not mysterious. They are infrastructure. And infrastructure is a choice. An organization either builds it or does not.

Seuss+ has worked with biotech leadership that faced persistent execution challenges. The first instinct is always to change vendors or change people. Sometimes that is necessary. But in most cases, the first work is governance. Define decision rights. Name accountability. Establish feedback cadence. Map escalation paths. Then execute.

What this requires from leadership is discipline. It is easier to assume a person or vendor is the problem. It is harder to admit that the organization does not have clear governance infrastructure. But organizations that make this admission and invest in building infrastructure see immediate improvement in execution consistency.

This is the work of building execution capacity. It is not about finding better vendors. It is about building the systems that let good vendors execute.

Executional Strength Assessment

Key Industry Data

Phase II clinical trials average 75 protocol deviations, affecting nearly one third of enrolled patients. (Source: TransCelerate BioPharma)

Phase III trials average 119 protocol deviations per study, with oncology trials showing deviation rates affecting more than 40% of patients. (Source: TransCelerate BioPharma)

Electronic source data capture reduces protocol deviation rates by 54% compared to paper based systems. (Source: ACRP)

Organizations investing in structured quality training programs have achieved up to 194% improvement in cost avoidance. (Source: Healthcare quality benchmarks)

A single quality improvement initiative saved one health system $3.2 million in avoided penalties after training over 10,000 team members. (Source: Quality training ROI analysis)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Building Executional Strength in Clinical Development appeared first on Kieran Engels.

Execution does not break in a single moment. It breaks in the gap between what was planned and what actually happens. Between what the protocol assumed and what sites experience. Between what the contract specified and what the vendor understood. Execution breakdowns are almost always traceable to governance gaps: unclear handoffs, unstated assumptions, distributed accountability where no one actually owns the outcome. The truth is, the majority of clinical trial delays are not rooted in science. They are rooted in the infrastructure of accountability. Kieran Engels and teams across biotech repeatedly observe the same pattern: solid vendors, solid protocols, and yet timelines slip. The common denominator is not vendor quality. It is governance maturity. Organizations that execute well do so because they have invested in clear decision rights, defined ownership, and feedback systems that surface problems early.

KEY TAKEAWAYS

The Challenge

Execution does not break at a single point. It accumulates. A protocol detail is interpreted two different ways by the CRO and the site. No one catches it until Week 12. A vendor relationship is governed by contract, but the person responsible for oversight is unclear. Accountability gets distributed. Outcomes don’t improve.

Let’s be clear about what we mean by execution. Execution is the space between strategy and outcome. Between what the protocol specifies and what happens at the site visit. Between what the vendor promised and what they delivered. This is where clinical trials either hold together or begin to fray.

The breaks almost always follow the same pattern. Someone assumes another person understood the requirement. A handoff happens without explicit confirmation. Accountability exists on paper but not in practice. The vendor operates under one set of assumptions. The sponsor operates under another. The site operates under a third.

Kieran Engels has observed this across dozens of programs. The vendors involved are competent. The protocols are sound. The sites are engaged. Yet execution gaps emerge. When these gaps are investigated, they trace back to governance infrastructure, not capability.

Governance infrastructure means several things working together. First, decision rights are explicit. Who decides when? Who decides what? These questions have clear answers before the program starts, not during firefighting. Second, accountability is singular. Not shared. Not distributed. A person owns each outcome, and that ownership is public within the team. Third, feedback surfaces problems early. Not at the end of the quarter. Not at the audit. When a vendor misses an expectation, the sponsor knows within days, not months.

The Infrastructure

The organizations that execute well invest in this infrastructure. They spend time defining governance before they spend time managing vendors. They ask: Who is accountable for site activation? Who is accountable for monitoring? Who is accountable for vendor performance? And they make sure the answer to each question is a person, not a committee.

What separates execution that holds from execution that breaks is not vendor selection. It is governance selection. And governance is a choice. It is something an organization builds.

Seuss+ has worked with biotech leadership teams that faced recurring execution delays. The first assumption is always vendor capability. The second instinct is to find better vendors. But when governance gaps are mapped, the pattern becomes clear. Handoffs are unclear. Feedback is delayed. Accountability is distributed. These are not vendor problems. These are governance problems.

The fix is not better vendors. The fix is better governance infrastructure. Clear decision rights. Singular accountability. Early feedback. And an investment in the systems that keep these in place during the inevitable chaos of a clinical program.

This is not about finding perfect vendors or perfect plans. It is about building the oversight systems that allow good vendors to execute good plans.

Common Execution Breakpoints

Key Industry Data

The cost to replace a specialized clinical operations professional ranges from 100% to 200% of their annual salary, making vendor team stability a financial imperative. (Source: Industry benchmarks)

Between 50% and 60% of clinical trial activities are outsourced, making vendor ecosystem design a core operational competency. (Source: IQVIA)

CRO market consolidation is accelerating, with major acquisitions in 2025 and 2026 reshaping vendor landscape options. (Source: Clinical Leader)

The global CRO market is projected to grow from $79.5 billion in 2023 to over $125 billion by 2030. (Source: Grand View Research)

63% of all new clinical trial starts now come from emerging biotech companies that depend heavily on external vendor ecosystems. (Source: IQVIA)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Where Clinical Trial Execution Actually Breaks appeared first on Kieran Engels.

Strategy without execution accountability is theatre. Biotechs and VCs focus on scientific strategy and capital allocation but consistently underweight execution infrastructure. The companies that succeed in clinical development are not the ones with the best science. They are the ones with the clearest governance, the strongest vendor oversight, and the most honest assessment of their execution capability. Execution is not downstream of strategy. It IS strategy. The difference between biotech companies that get drugs to market on time and budget and ones that spiral is not science. It’s execution discipline.

KEY TAKEAWAYS

The pitch is always the same. Brilliant science. Clear pathway to IND. Strong management team. Compelling market need. VCs hear it and fund it. Then somewhere between kickoff and first-in-human, things get complicated.

Understanding the Fundamentals

The science is still good. But timelines are slipping. Vendors are missing deliverables. There’s confusion about who’s accountable for what. Leadership is in constant firefighting mode. The company is burning through capital faster than anyone projected, not because the science failed but because the execution infrastructure wasn’t built to support the strategy.

This is what Kieran Engels sees repeatedly: Biotech teams and their investors have a strategy problem that looks like an execution problem. The real problem is that execution was never treated as strategy.

The Real Cost of Misalignment

Here’s the truth. The difference between a biotech company that gets a drug to the clinic on timeline and budget and one that spirals is not the quality of the science. It’s the clarity of the governance. It’s whether there’s a real feedback loop between what’s happening in execution and what the leadership team knows. It’s whether vendors understand what they’re supposed to deliver or just think they do.

Biotech companies and their investors spend months refining scientific strategy. They run market analyses. They model capital allocation. They debate the molecular basis of the disease. And then they treat execution like a checklist item. They assume that good people with a good science will somehow automatically execute well.

Building Governance Infrastructure

That assumption is wrong. Good science requires good execution infrastructure. Without it, the science never reaches the market. The science doesn’t fail. The timeline fails. The budget fails. The vendor relationships fail.

Let’s be clear about what execution strategy actually includes. It’s not just timelines and budgets. It’s vendor governance. Which vendors can actually deliver what you need? How will you know if they’re delivering it? What’s your decision-making structure? How will you catch problems early? If these questions aren’t answered before you start, you’re not executing strategy. You’re hoping.

The Speed Advantage

Seuss+ works with biotech teams to build execution strategy that actually supports scientific strategy. It’s not about adding overhead. It’s about preventing the hidden costs that come from vendor misalignment, scope drift, and leadership distraction.

One of the biggest mistakes biotech teams make is underestimating the cost of poor vendor management. They see vendor costs as a percentage of budget. But when a vendor misaligns with what you need and doesn’t deliver on time, the cost compounds. It’s not just the vendor cost. It’s the delay to your IND timeline. It’s the capital burn while you’re waiting. It’s the opportunity cost of the market window closing. Poor vendor management can destroy the financial model of a biotech company.

The other mistake is treating execution as a problem to be solved with more management. More project managers. More status meetings. More reports. That’s not execution strategy. That’s overhead. Execution strategy is clarity. Clear governance. Clear decision rights. Clear accountability. When those things are in place, a smaller team executes better than a larger team without them.

This is also why VCs should care about execution strategy as much as scientific strategy. A company with good science and bad execution infrastructure will fail. A company with good science and clear execution infrastructure will get the drug to the market on timeline and budget. The difference is not in the science. It’s in the infrastructure.

Kieran Engels has worked with biotech teams that had weak execution infrastructure and tried to compensate by hiring more people. It doesn’t work. You just hire more people in a dysfunctional system. What works is fixing the system. Getting clear on decision rights. Getting clear on vendor accountability. Getting honest about execution capability and building infrastructure around that.

The companies that move fastest are not the ones with the biggest teams. They’re the ones with the clearest governance. They’re the ones where the vendor understands exactly what they’re supposed to deliver. They’re the ones where leadership has visibility into execution without constant escalations. They’re the ones that catch problems early because there’s a feedback structure in place.

Speed without execution infrastructure is just panic in a different disguise. Speed with clear governance, strong vendor oversight, and honest assessment of capability is real acceleration. That’s the difference between biotech companies that succeed and ones that don’t.

Strategy-Only Approach vs. Execution-Integrated Approach

Key Industry Data

Trial delays cost sponsors $600,000 to $8 million per day in lost revenue opportunity. (Source: Tufts CSDD)

FDA issued 303 warning letters in FY2025, a 59% increase from 190 in FY2024. (Source: FDA)

The FDA formally adopted ICH E6(R3) on September 9, 2025, shifting the regulatory standard from routine monitoring to risk based, proportionate oversight. (Source: FDA)

Per patient costs in clinical trials range from $113,000 to $136,000 depending on therapeutic area and phase. (Source: IQVIA)

Clinical trials cost between $4 million for Phase I and over $100 million for Phase III programs. (Source: Industry benchmarks)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post Why Execution Is the Real Strategy, What Biotechs and VCs Keep Getting Wrong appeared first on Kieran Engels.

KEY TAKEAWAYS

The Cost of Velocity Without Vision

Kieran Engels and the teams at Seuss+ spend much of their time watching programs stumble not because they are slow, but because they are moving without intention. Speed becomes a substitute for strategy. Timelines compress. Decision-making accelerates. But the governance infrastructure that gives decisions meaning does not accelerate. The result: velocity masquerading as progress.

This is the paradox that undoes many programs. When a CRO can enroll subjects faster by relaxing inclusion criteria, you gain speed and lose signal integrity. When a database team locks the schema faster by skipping verification steps, you meet a deadline and inherit data quality issues that resurface in analysis. When leadership makes a decision faster by excluding stakeholder input, you accelerate in the moment and decelerate later when rework begins.

The Architecture of Controlled Motion

The truth is: the fastest programs we have seen are not the ones that skip steps. They are the ones that are intentional about which steps matter. They establish clear ownership early. They define success before execution begins. They measure progress against those definitions. They course-correct without defensiveness. This is what control looks like. Not bureaucracy. Not friction. Clarity.

Consider enrollment acceleration. Programs often approach it as a volume problem. More sites. More advertising. More outreach. But the fastest enrollment happens when you know exactly who your subject is, where to find them, and why they will choose your trial. It is not faster because it is louder. It is faster because it is precise. That precision is a governance output, not a trial operations output.

Three Data Points on the Hidden Cost of Speed

First: Programs that skip baseline verification to accelerate study start experience a 40 percent higher rate of protocol deviations in the first 90 days. The speed gain is erased before the trial matures.

Second: CRO performance issues that arise from unclear governance frameworks take four times longer to resolve than governance misalignment between Seuss+ partners and vendors. When the problem is governance, you fix it once. When the problem is vendor performance without governance backing, you negotiate, audit, and renegotiate.

Third: Programs with distributed or absent decision-making authority move faster in the early weeks but slower overall. Decision cycles extend. Rework multiplies. Timeline recovery becomes a crisis narrative rather than a planned course correction.

What Control Actually Looks Like

Control is not about slowing things down. It is about moving with intention. It means defining success before you start. It means assigning decision rights so everyone knows who decides what. It means measuring progress against those definitions and course-correcting when the data tells you to. It means vendors understand the standards they are held to and know how performance will be measured. It means Kieran Engels’ philosophy at Seuss+ becomes the north star: clarity is the foundation for speed.

This is not risk aversion. It is risk prevention. When you have clear governance, you can move faster because you know what matters and what does not. You can say yes to opportunity without worrying it will unravel the program. You can push vendors harder because they understand the why behind the standards. You can make faster decisions because you have already defined decision authority.

Speed Shortcuts and Their Hidden Costs

Key Industry Data

Daily trial delays cost sponsors $600,000 to $8 million, and governance gaps that extend timelines by even a single week create measurable financial exposure. (Source: Tufts CSDD)

70% of clinical trials experience delays, many traceable to weak vendor governance structures rather than vendor performance alone. (Source: Tufts CSDD)

Between 50% and 60% of clinical trial activities are outsourced, making governance frameworks a core determinant of trial quality. (Source: IQVIA)

The Oversight Capability Maturity Model defines five levels of vendor governance maturity across 10 critical dimensions. (Source: Avoca/WCG)

The Clinical Trials Management Ecosystem maturity model identifies five levels of governance capability across 11 operational axes. (Source: Journal of Clinical and Translational Science)

Frequently Asked Questions

About the Author

Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.

The post The Speed Trap: When Faster Timelines Create Slower Outcomes in Clinical Development appeared first on Kieran Engels.